8 / 36
Profile 1014
PFS Crizotinib vs Chemotherapy
Shaw AT, et al. N Engl J Med 2013;368:2385–94
Endpoint
ORR %
74%
Median PFS
10.9 months
Median duration of response
11.3 months
0
5
10
15
20
35
PFS probability
1.0
0.8
0.6
0.4
0.2
0
HR=0.45 (0.35–0.60)
Log-rank p<0.0001
Crizotinib (n=172)
Chemotherapy (n=171)
Time (months)
25
30
10.9 months
7.0 months